Gregory M. Lanza, MD, PhD, FACC
Professor of Medicine, Biomedical Engineering, and Biology and Biomedical Sciences
Phone314-454-8635
Emailgreg@cvu.wustl.edu
Additional Titles
- Co-Founder, Chief Scientific Officer and Board Member, Kereos, Inc. , St. Louis, MO
- Oliver M. Langenberg Chair, Distinguished Professor of the Science and Practive of Medicine
Related Links
Education
- Bachelor of Arts: Colby College, Waterville, MN (1975)
- Masters of Science: Department of Poultry Science, University of Georgia, Athens, GA (1978)
- Doctor of Philosophy: Department of Poultry Science, University of Georgia, Athens, GA (1981)
- Doctor of Medicine: Northwestern University Medical School, Chicago, IL (1992)
- Residency, Medicine: Department of Medicine, Barnes Hospital, Washington University Medical Center, St. Louis, MO (1994)
- Fellowship, Cardiology: Barnes-Jewish Hospital, Washington University Medical Center, St. Louis, MO (1999)
Board Certifications
- Cardiovascular Disease
Recognition
Phi Kappa Phi Honor Society
Gamma Sigma Delta Agricultural Honor Society
1997
American Heart Association Fellowship, Missouri Affiliate (1995-1997)
Bristol-Myers Squibb Fellowship Award
1998
Bracco Diagnostics Inc./Society for Cardiac Angiography and Interventions Fellowship
ACC/Littmann Scholarship Award
2000
American College of Cardiology, Searle Career Development Award (2000)
2001
American Heart Association, Missouri Affiliate – Beginning Grant (1999-2001)
Barnes-Jewish Hospital Research Foundation Award (1999-2001)
2003
NCI Unconventional Innovation Program Awards (2000-2003, 2002-2005, 2003-2006)
2005
NCI Unconventional Innovation Program Awards (2000-2003, 2002-2005, 2003-2006)
2006
NCI Unconventional Innovation Program Awards (2000-2003, 2002-2005, 2003-2006)
Clinical Interests
Noninvasive general adult cardiology with clinical emphasis on cardiovascular imaging with echocardiography and magnetic resonance imaging.
Research Interests
Development of novel nanotechnologies for biomedical molecular imaging (Echo, MRI, CT, Photoacoustic tomography, and optical) and targeted drug delivery (chemotherapeutic, thrombolytic, and siRNA/RNAi) in cardiovascular, neurological, inflammatory, and cancer disease. Design and development of novel prodrugs inclusion in lipid-based nanocolloid agents (including chemotherapeutic, peptides, natural products, synthetic biochemical pathway inhibitors).